You are here

BioFulcrum Heart Failure Research Program

To guide successful drug discovery or heart regeneration, the scientific community must gain a better understanding of the relationship within and among heart cells, both in health and disease.

Scientists in this BioFulcrum program combine their complementary expertise to illuminate the blueprint of the heart at every level: cellular, molecular, protein, genetic, functional, and regulatory. Together, they will overcome current roadblocks and produce tools and knowledge assets to enable two critical clinical goals: human heart regeneration to improve the heart after failure and disease modeling to identify potential therapies for cardiomyopathy.

In 2016, Gladstone launched Tenaya Therapeutics Inc., the first biopharmaceutical spin-off company formed out of BioFulcrum. Building on Gladstone’s cardiovascular research, Tenaya aims to accelerate the discovery of cures by concentrating on regenerative medicine and drug discovery for heart failure.

Program Objectives

  • Build a strong foundation of molecular and cellular tools to deeply interrogate heart cells
  • Create human heart cells that are of sufficient quality to faithfully recapitulate model normal and diseased states as a platform for drug discovery and/o personalized medicine approaches
  • Pioneer techniques to promote cardiac regeneration in failing hearts

Scientific Partners

Benoit Bruneau, PhD, Gladstone Institutes

Bruce Conklin, MD, Gladstone Institutes

Saptarsi Haldar, MD, Gladstone Institutes

Nevan Krogan, PhD, Gladstone Institutes, UC San Francisco

Todd McDevitt, PhD, Gladstone Institutes

Katie Pollard, PhD, Gladstone Institutes

Deepak Srivastava, MD, Gladstone Institutes

Shinya Yamanaka, MD, PhD, Gladstone Institutes, Kyoto University